At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IMRX Immuneering Corp
Post-Mkt 01-14 17:13:00 EST
4.43
+0.30
+7.13%
盘后4.47
+0.04+0.90%
17:12 EST
High4.49Low4.16Vol2.25M
Open4.22D1 Closing4.14Amplitude7.96%
Mkt Cap286.04MTradable Cap241.04MTotal Shares64.57M
T/O9.78MT/O Rate4.14%Tradable Shares54.41M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Immuneering updated 12-month data for atebimetinib ‘encouraging,’ says Leerink
TIPRANKS  ·  01-09
Immuneering updated 12-month data for atebimetinib ‘encouraging,’ says Leerink
Immuneering Down Nearly 40%, on Pace for Largest Percent Decrease Since March 2024 -- Data Talk
Dow Jones  ·  01-09
Immuneering Down Nearly 40%, on Pace for Largest Percent Decrease Since March 2024 -- Data Talk
Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Benzinga  ·  01-08
Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Stock Market Today: S&P 500, Dow Jones Futures Decline — AZZ, Northrop Grumman, Immuneering In Focus
Benzinga  ·  01-08
Stock Market Today: S&P 500, Dow Jones Futures Decline — AZZ, Northrop Grumman, Immuneering In Focus
Immuneering Corp (IMRX.US) Plunges 21% After-Hours Despite Pancreatic Cancer Therapy Outperforming Standard of Care, Lagging Behind Competitors
Stock News  ·  01-08
Immuneering Corp (IMRX.US) Plunges 21% After-Hours Despite Pancreatic Cancer Therapy Outperforming Standard of Care, Lagging Behind Competitors
Immuneering Reports 64% 12-Month Overall Survival in Phase 2a Pancreatic Cancer Trial
Reuters  ·  01-08
Immuneering Reports 64% 12-Month Overall Survival in Phase 2a Pancreatic Cancer Trial
Immuneering Announces Exceptional 64% Overall Survival at 12 Months in First-Line Pancreatic Cancer Patients Treated With Atebimetinib + Mgnp
THOMSON REUTERS  ·  01-08
Immuneering Announces Exceptional 64% Overall Survival at 12 Months in First-Line Pancreatic Cancer Patients Treated With Atebimetinib + Mgnp
Immuneering Corp - to Dose First Patient in Phase 3 Trial Mid-2026
THOMSON REUTERS  ·  01-08
Immuneering Corp - to Dose First Patient in Phase 3 Trial Mid-2026
Institutional investors control 36% of Immuneering Corporation (NASDAQ:IMRX) and were rewarded last week after stock increased 19%
Simply Wall St.  ·  2025-12-27
Institutional investors control 36% of Immuneering Corporation (NASDAQ:IMRX) and were rewarded last week after stock increased 19%
BRIEF-Immuneering To Announce 12-Month Overall Survival Data From Phase 2A Clinical Trial Of Atebimetinib + mGnP
Reuters  ·  2025-12-23
BRIEF-Immuneering To Announce 12-Month Overall Survival Data From Phase 2A Clinical Trial Of Atebimetinib + mGnP
Immuneering to Announce 12-Month Survival Data from Phase 2a Pancreatic Cancer Trial
Reuters  ·  2025-12-23
Immuneering to Announce 12-Month Survival Data from Phase 2a Pancreatic Cancer Trial
Immuneering to Announce 12-Month Overall Survival Data From Phase 2a Clinical Trial of Atebimetinib + Mgnp in First-Line Pancreatic Cancer Patients on January 7, 2026
THOMSON REUTERS  ·  2025-12-23
Immuneering to Announce 12-Month Overall Survival Data From Phase 2a Clinical Trial of Atebimetinib + Mgnp in First-Line Pancreatic Cancer Patients on January 7, 2026
BRIEF-Immuneering Advances Towards Dosing First Patient In Phase 3 Atebimetinib Trial
Reuters  ·  2025-12-18
BRIEF-Immuneering Advances Towards Dosing First Patient In Phase 3 Atebimetinib Trial
Immuneering: Expects to Share Topline Results From Trial in Mid-2028
THOMSON REUTERS  ·  2025-12-18
Immuneering: Expects to Share Topline Results From Trial in Mid-2028
Immuneering Expects to Dose First Patient in Global Phase 3 Registrational Trial, Mapkeeper 301, in Mid-2026
THOMSON REUTERS  ·  2025-12-18
Immuneering Expects to Dose First Patient in Global Phase 3 Registrational Trial, Mapkeeper 301, in Mid-2026
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA
GlobeNewswire  ·  2025-12-18
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA
Immuneering Corporation joins Nasdaq Biotechnology Index
Reuters  ·  2025-12-16
Immuneering Corporation joins Nasdaq Biotechnology Index
Immuneering Corporation to Present at Piper Sandler Annual Healthcare Conference
Reuters  ·  2025-11-25
Immuneering Corporation to Present at Piper Sandler Annual Healthcare Conference
U.S. RESEARCH ROUNDUP-Alignment Healthcare, BJ's Wholesale Club Holdings, Hyatt Hotels
Reuters  ·  2025-11-24
U.S. RESEARCH ROUNDUP-Alignment Healthcare, BJ's Wholesale Club Holdings, Hyatt Hotels
Immuneering Showcases Promising Phase 2 Pancreatic Cancer Data for Atebimetinib Combination
Reuters  ·  2025-11-22
Immuneering Showcases Promising Phase 2 Pancreatic Cancer Data for Atebimetinib Combination

Introduction

Company Name.
Immuneering Corp
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Issue price:
--